• Amgen has reported positive Phase 3 results for a new subcutaneous, on-body injector formulation of Tepezza for Thyroid Eye Disease.
• The late stage trial found that the on-body injector delivered comparable efficacy and safety to the already approved intravenous version.
• This new formulation is aimed at offering a more convenient treatment option as competition in Thyroid Eye Disease increases.

For investors watching NasdaqGS:AMGN, this update comes with the shares trading around $340.0 and a 1 year return of 25.1%. Over 3 and 5 years, returns of 48.6% and 59.1% indicate the stock has been rewarding patient holders, alongside a recent 7 day decline of 3.4% and a 30 day decline of 8.0%.

The new on-body injector version of Tepezza could broaden access for Thyroid Eye Disease patients who prefer or require treatment outside an infusion setting. As competition in this space builds, readers may want to watch how quickly Amgen can progress regulatory filings and how potential uptake develops once any approvals are in place.

Stay updated on the most important news stories for Amgen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amgen.

The Phase 3 Tepezza on body injector data matters because it helps Amgen defend an existing franchise while trying to expand the Thyroid Eye Disease market. A 77% proptosis response rate versus 19.6% on placebo, with a safety profile described as broadly consistent with the intravenous version, suggests Amgen is not trading efficacy for convenience. For you as an investor, the key angle is that a subcutaneous, at home style option could make treatment more accessible to patients who would otherwise avoid or delay infusion center visits, at a time when an emerging rival is trying to compete on convenience. That may support Tepezza’s role in Thyroid Eye Disease even as new entrants arrive, but it also keeps the focus on ongoing safety monitoring, including known risks such as infusion reactions, hyperglycemia, inflammatory bowel disease flares and hearing issues.

How This Fits Into The Amgen Narrative

• The Tepezza on body injector aligns with the existing narrative that Amgen is leaning on late stage, specialty therapies to serve under treated chronic conditions, in this case Thyroid Eye Disease.
• Bringing a new formulation into the market while drug pricing pressure and biosimilar competition build could make it harder to maintain margins if payers push for discounts in return for the added convenience.
• The narrative focuses heavily on obesity, cardiovascular and oncology programs, so the potential impact of a more convenient Tepezza delivery option on rare disease reach and brand durability may not be fully captured.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Amgen to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Known Tepezza risks such as infusion reactions, hyperglycemia, inflammatory bowel disease exacerbation and potential hearing impairment require ongoing monitoring and could draw regulatory attention if safety signals change.
• ⚠️ If payers view the on body injector as a convenience upgrade rather than a clinical step change, reimbursement terms could limit the economic upside of the new formulation.
• 🎁 A subcutaneous on body injector that matches intravenous efficacy may help Amgen retain share in Thyroid Eye Disease as competitors like Viridian Therapeutics seek to differentiate on dosing convenience.
• 🎁 A more flexible administration option can support broader treatment use in moderate to severe Thyroid Eye Disease, which aligns with Amgen’s focus on chronic, specialty conditions with significant unmet need.

What To Watch Going Forward

From here, the main things to track are how quickly Amgen files for regulatory approvals of Tepezza on body injector, what label language and safety monitoring requirements regulators include, and how payers treat the new formulation versus the intravenous version on formularies. Once approval decisions arrive, prescription trends for both intravenous and on body injector Tepezza, together with commentary from Amgen on patient mix and duration of therapy, will give a clearer sense of whether this new option is defending share or expanding the Thyroid Eye Disease market. It is also worth watching how competitors such as Viridian Therapeutics and any future entrants position their own Thyroid Eye Disease offerings on convenience, pricing and safety.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Amgen, head to the community page for Amgen to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.